Health sciences company PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) stated on Wednesday that it plans to launch the clinical trials of its cannabinoid Sol-gel to reduce the possibility of contracting coronavirus infections.
In conjunction with the COVID-19 Sol-Gel clinical programme, the company has retained Veristat, a global clinical research organization (CRO) located in Massachusetts, USA, to assist with planning the clinical trial process and writing the required protocols.
Pursuant to the consulting agreement, Veristat will provide services to design and develop PreveCeutical COVID-19 Sol-Gel clinical programme and required protocol.
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
4basebio announces expansion of DNA offering for personalised mRNA medicines
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease